Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) Depreciation & Amortization - Total (2020 - 2025)

Agilon Health (AGL) has disclosed Depreciation & Amortization - Total for 6 consecutive years, with -$10.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization - Total fell 38.89% year-over-year to -$10.0 million, compared with a TTM value of $1.5 million through Dec 2025, down 6.25%, and an annual FY2025 reading of $1.5 million, down 11.76% over the prior year.
  • Depreciation & Amortization - Total was -$10.0 million for Q4 2025 at Agilon Health, down from $3.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $3.9 million in Q2 2025 and bottomed at -$10.0 million in Q4 2025.
  • Average Depreciation & Amortization - Total over 5 years is $555000.0, with a median of $1.3 million recorded in 2022.
  • Peak annual rise in Depreciation & Amortization - Total hit 200.0% in 2023, while the deepest fall reached 416.67% in 2023.
  • Year by year, Depreciation & Amortization - Total stood at $500000.0 in 2021, then soared by 140.0% to $1.2 million in 2022, then tumbled by 416.67% to -$3.8 million in 2023, then tumbled by 89.47% to -$7.2 million in 2024, then tumbled by 38.89% to -$10.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for AGL at -$10.0 million in Q4 2025, $3.8 million in Q3 2025, and $3.9 million in Q2 2025.